(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 17 October 2016 - Actelion Ltd (SIX: ATLN) announced today that a series of recently published scientific articles [1,2,3,4,5] describing the unique profile of the company's orally-active antimalarial compound, ACT-451840, has reinvigorated interest in the compound. Actelion is in discussions to find a partner with the expertise and resources to bring this promising therapy to patients. ACT-451840 appears to have a distinct mode of action that sets it apart from current antimalarial drugs, including artemisinins. It has a rapid onset of action as well as activity on all blood-borne (erythrocytic) stages, which is retained against multiple...
↧